Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer

Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC)

(2017) J. F. Vansteenkiste et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study

(2017) N. Altorki et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032–18031)

(2017) J. Louahed et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031)

(2017) W. H. Kruit et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Analysis-Based Treatment Strategies for Non–Small Cell Lung Cancer

(2017) Gerold Bepler et al.   Cancer Control

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

(2010) Rodryg Ramlau et al.   Journal of Thoracic Oncology

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients

(2009) V. Ludovini et al.   ANNALS OF ONCOLOGY

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer

(2009) Edward S. Kim et al.   CANCER

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer

(2009) Shin-ichi Yamashita et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Recent advances of novel targeted therapy in non-small cell lung cancer

(2009) Jed A Katzel et al.   Journal of Hematology & Oncology

Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen

(2009) Stuart Salmon et al.   Journal of Thoracic Oncology

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

The cancer vaccine roller coaster

(2009) Bruce Goldman et al.   NATURE BIOTECHNOLOGY

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

(2009) N. A. Pennell et al.   ONCOLOGIST

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies

(2008) P. A. Bradbury et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

(2008) Vincent G Brichard et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Bevacizumab for the treatment of advanced non-small-cell lung cancer

(2008) Christian Manegold   Expert Review of Anticancer Therapy

Gefitinib for the treatment of non-small-cell lung cancer

(2008) Toyoaki Hida et al.   Expert Review of Anticancer Therapy

Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer

(2008) Elia Neninger Vinageras et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Comparing Carboplatin, Paclitaxel, and Bexarotene With Carboplatin and Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT II

(2008) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY

Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung Cancer

(2008) Elia Neninger et al.   JOURNAL OF IMMUNOTHERAPY

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma

(2008) Martin Reck et al.   LUNG CANCER

Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation

(2008) I. Abdel Salam et al.   MEDICAL ONCOLOGY

EGFR-targeted therapies in lung cancer: predictors of response and toxicity

(2008) Rebecca Suk Heist et al.   PHARMACOGENOMICS

About human tumor antigens to be used in immunotherapy

(2008) S. Lucas et al.   SEMINARS IN IMMUNOLOGY

Targeted Therapy in Advanced Non-Small-Cell Lung Cancer

(2008) Scott Gettinger   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

(2007) R. Rosell et al.   ANNALS OF ONCOLOGY